WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced that it has received FDA approval for the REBEL Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease. The company announced CE Mark for the Rebel Stent System in February.
The REBEL Stent System expands the Boston Scientific family of stents featuring its proprietary platinum chromium (PtCr) alloy and a customized stent architecture design. The REBEL Stent offers the identical stent platform as the Promus PREMIER Drug-Eluting Stent (DES) but without the Everolimus drug.
Copyright RTT News/dpa-AFX